Related Resources for this page:
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Future Directions
- Antibody-Drug conjugates
- Summary
- A brief history of ADCs
- Cancer effects
- Current research in ADCs
- Cytotoxic agent
- Emerging therapeutic options
- Emerging therapeutic options
- HER2
- HER ligands
- HER pathways slide decks and videos
- Glossary
- Receptor activation
- Dimerization
- HER Signaling
- Overview
- HER1/EGFR evaluation
- HER1/EGFR and prognosis
- HER1/EGFR as a therapeutic target
- Summary
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER2 dysregulation
- HER2:HER3 dimer
- HER2 and prognosis
- HER2 detection methods
- HER2 as a therapeutic target
- HER2 in breast cancer
- Summary
- HER2 in ovarian cancer
- HER3 dysregulation
- HER3
- HER3 evaluation
- HER3 as a therapeutic target
- HER3 in breast cancer
- HER3 in ovarian cancer
- HER4
- How are ADCs designed to work?
- Glossary
- Monoclonal antibody
- Multimedia Resources
- Receptor-Mediated Endocytosis
- Research ADCs
- Research MET
- Stable linker
- HER receptors
- Summary
- Targeting cancers with ADCs
- Therapeutic potential of HER pathways
- What are ADCs?
- What is Met?
- Apoptosis
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- Non-Antibody Biologics
- Targeted Small Molecules
- Summary
- Apoptosis
- Apoptotic pathways
- The Bcl-2 family
- Cancer effects
- Apoptosis
- Emerging therapeutic options
- Emerging therapeutic options
- HER2
- Gastric Cancer
- HER ligands
- HER pathways slide decks and videos
- Glossary
- Receptor activation
- Dimerization
- Overview
- HER1/EGFR evaluation
- HER1/EGFR and prognosis
- HER1/EGFR as a therapeutic target
- Summary
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER2 dysregulation
- HER2:HER3 dimer
- HER2 and prognosis
- HER2 detection methods
- HER2 as a therapeutic target
- HER2 in breast cancer
- Summary
- HER2 in ovarian cancer
- HER3 dysregulation
- HER3
- HER3 evaluation
- HER3 as a therapeutic target
- HER3 in breast cancer
- HER3 in ovarian cancer
- HER4
- Glossary
- MAPK Signaling
- MEK Inhibitor (GDC-0973)
- Emerging therapeutic options
- PI3K Inhibitor (GDC-0941)
- Reactivating apoptosis
- Research MET
- HER receptors
- Summary
- PI3K/Akt/mTOR Signaling
- Therapeutic potential of HER pathways
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
- What is Met?
- Traditional Monoclonal Antibodies
- Summary
- Anti-EGFL7
- B-cell Surface Proteins
- Cancer effects
- Glossary
- Direct cell death
- Emerging therapeutic options
- Emerging therapeutic options
- HER2
- Gastric Cancer
- HER ligands
- HER pathways slide decks and videos
- Glossary
- Receptor activation
- Dimerization
- HER Signaling
- Overview
- HER1/EGFR evaluation
- HER1/EGFR and prognosis
- HER1/EGFR as a therapeutic target
- Summary
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER2 dysregulation
- HER2:HER3 dimer
- HER2 and prognosis
- HER2 detection methods
- HER2 as a therapeutic target
- HER2 in breast cancer
- Summary
- HER2 in ovarian cancer
- HER3 dysregulation
- HER3
- HER3 evaluation
- HER3 as a therapeutic target
- HER3 in breast cancer
- HER3 in ovarian cancer
- HER4
- Emerging therapeutic options
- Research MET
- HER receptors
- Summary
- Angiogenic Signaling
- Inhibition of HER2 dimerization
- Therapeutic potential of HER pathways
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
- What is Met?
- Antibody-Drug conjugates
Resisting apoptosis: a hallmark of cancer
Cancer cells that avoid apoptosis continue to proliferate uncontrollably, which results in an increased tumor mass. Resisting apoptosis is a key process in cancer development and progression (Figure 2.1).1,2
Adapted from Cell, 144, Hanahan D, Weinberg RA, The hallmarks of cancer: the next generation, 666-674, copyright © 2011, with permission from Elsevier.2
Cells resist apoptosis if they have an overexpression of anti-apoptotic proteins, such as Bcl-2, Bcl-XL, or IAP proteins. When these anti-apoptotic proteins are overexpressed, the cell’s ability to resist apoptosis is increased, and the cells will continue to proliferate, regardless of pro-apoptotic cues.2,10
Virtually all cancer cells are prone to resisting apoptosis.11 Understanding the mechanisms of resistance to apoptosis may lead to the development of therapies that can reprogram cell death.2